Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging immunotherapeutic approach that is revolutionizing cancer treatment. The impressive clinical results obtained with CAR-T cell therapy in patients with acute lymphoblastic leukemia and lymphoma have fueled the development o...

Full description

Bibliographic Details
Main Authors: Marijke Timmers, Gils Roex, Yuedi Wang, Diana Campillo-Davo, Viggo F. I. Van Tendeloo, Yiwei Chu, Zwi N. Berneman, Feifei Luo, Heleen H. Van Acker, Sébastien Anguille
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor-modified T cells
immunotherapy
multiple myeloma
B cell maturation antigen
CD19
CD138
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01613/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01613/full

Similar Items